Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
5-hydroxy-2-(4-hydroxyphenyl)-1-benzofuran-7-carbonitrile is a synthetic small molecule belonging to the class of organic compounds known as 2-arylbenzofuran flavonoids[2]. It has been studied primarily as a potent and selective ligand for estrogen receptors, with high affinity for estrogen receptor beta (ERβ) and moderate affinity for estrogen receptor alpha (ERα)[4]. In binding assays, it demonstrated an IC50 of approximately 46 nM for ERα and an IC50/EC50 in the low nanomolar range (about 2 nM) for ERβ[4]. The compound is not currently approved or marketed as a pharmaceutical drug but has been investigated in preclinical research settings.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on 5-hydroxy-2-(4-hydroxyphenyl)-1-benzofuran-7-carbonitrile.